Verici Dx PLC (GB00BM8HZD43)
XSTU 
EXPM Primary XSTU Summary
GB00BM8HZD43 Chart
Verici Dx gains Olink Certified Service Provider status to expand proteomics offering
Verici Dx PLC (AIM:VRCI) has become an Olink Certified Service Provider, allowing the transplant diagnostics company to offer Olink-based proteomics assay services from its CAP-certified and CLIA-accredited laboratory. The certification, part of Thermo Fisher's Life Sciences Solutions network, enables Verici Dx to support biomarker discovery, algorithm development, validation, clinical trials and diagnostic applications for both external clients and its own development pipeline.
Verici Dx rises after passing key US laboratory accreditation audit
Verici Dx PLC (AIM:VRCI) shares were up as much as 11% in early trading after the diagnostics company announced it had successfully completed its second biennial inspection by the College of American Pathologists (CAP), one of the leading US bodies for clinical laboratory accreditation. The inspection passed with no deficiencies, confirming the company's continued compliance with CAP's rigorous quality and operational standards.
Verici Dx climbs on 'preferred provider' deal with US healthcare network
Verici Dx PLC (AIM:VRCI) shares skipped 12% higher to 0.7p after the developer of diagnostic tests for organ transplants bagged a new agreement with a healthcare network in the United States. The deal with Prime Health Services sees Verici Dx join a preferred provider network, giving its services access to more than 850,000 healthcare providers and 35 million insurance claims a year.
Verici Dx PLC (GB00BM8HZD43) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Verici Dx PLC ever had a stock split?
Verici Dx PLC Profile
| Biotechnology Industry | Healthcare Sector | Harpreet Singh Sangha CEO | XSTU Exchange | US92337L2034 ISIN |
| US Country | 1 Employees | - Last Dividend | 30 Mar 2012 Last Split | - IPO Date |
Overview
Verde Science, Inc., originally known as Rango Energy, Inc., underwent a significant transformation in May 2014 when it changed its name and refocused its corporate strategy. Founded in 2007 and headquartered in Dallas, Texas, this pharmaceutical research and development company has since dedicated itself to the creation and development of a diverse portfolio of prescription medicines. These medicines are unique for being based on cannabinoids, compounds that have been increasingly recognized for their potential therapeutic benefits in a variety of medical conditions. Through its innovative approach, Verde Science aims to meet the growing demand for cannabinoid-based pharmaceuticals, leveraging its expertise in the field to address various healthcare needs.
Products and Services
- Cannabinoid-Based Prescription Medicines
At the heart of Verde Science's product portfolio are its cannabinoid-based prescription medicines. These products are developed following rigorous pharmaceutical research and development practices. Verde Science focuses on harnessing the therapeutic properties of cannabinoids—a set of compounds found in the cannabis plant—to formulate medications aimed at treating a wide range of medical conditions. This innovative approach reflects the company's commitment to exploring and utilizing the medicinal potential of cannabinoids, aligning with current trends and research that recognize the benefits these compounds can offer in the pharmaceutical landscape.
